Clinical trial · no report yet · Phase 2
RIGHT Choice
Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer
- NCT03839823 ↗
- Completed
- Novartis Pharmaceuticals
- 109 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 51 | |
| Podcasts | 42 | |
| X threads | 16 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Randomized Study of the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Physician Choice Chemotherapy in Premenopausal or Perimenopausal Patients With Hormone Receptor-positive/ HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Breast Cancer
- Interventions
- Docetaxel / Capecitabine; Capecitabine / Vinorelbine; Paclitaxel / Gemcitabine; Ribociclib; Letrozole OR Anastrozole; Goserelin
- Arms
- Ribociclib 600 mg · Experimental
- Combination Chemotherapy · Active comparator
- Enrollment
- 222
- Primary outcomes
- Progression-free Survival
- Sponsor
- Novartis Pharmaceuticals
- Start
- Feb 25, 2019
- Primary completion
- Apr 12, 2022
- Results posted
- Yes
- Registry record
- NCT03839823 · updated Oct 9, 2024
Publications
linked from the registry- Lu YS, Mahidin EIBM, Azim H, Eralp Y, Yap YS, Im SA, Rihani J, Gokmen E, El Bastawisy A, Karadurmus N, Lim YN, Lim CS, Duc LT, Chung WP, Babu KG, Penkov K, Bowles J, Alfaro TD, Wu J, Gao M, Slimane K, El Saghir NS. Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. J Clin Oncol. 2024 Aug 10;42(23):2812-2821. doi: 10.1200/JCO.24.00144. Epub 2024 May 21. PubMed 38771995